Overview

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.
Phase:
Phase 4
Details
Lead Sponsor:
Wei Zhao
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Treatments:
Anti-Infective Agents
Antineoplastic Agents
Asparaginase
Bortezomib
Dasatinib
Imatinib Mesylate
Lenograstim
Pegaspargase
Sargramostim